What are the recommended guidelines for Pap (Papanicolau) tests and Human Papillomavirus (HPV) testing for cervical cancer screening?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cervical Cancer Screening Guidelines

When to Start Screening

All women should begin cervical cancer screening at age 21 years, regardless of sexual activity history or HPV vaccination status. 1, 2 Do not screen women younger than 21 years under any circumstances, as cervical cancer incidence is extremely low in this age group even among sexually active women. 1, 3

Screening Strategy by Age Group

Ages 21-29 Years

  • Screen with Pap test alone every 3 years 1, 3
  • Do not use HPV testing (alone or with Pap) in this age group, as HPV infection is extremely common and usually clears spontaneously 1, 4
  • Annual screening is not recommended for any age group 1

Ages 30-65 Years

The preferred approach is co-testing (Pap test plus HPV DNA test) every 5 years. 1, 4, 3 This provides higher sensitivity than Pap testing alone and justifies the extended screening interval. 4

An acceptable alternative is Pap test alone every 3 years if co-testing is not available. 1, 3

When to Stop Screening

Women can discontinue screening at age 65 if they meet ALL of the following criteria: 1, 4, 3

  • ≥3 consecutive negative Pap tests OR ≥2 consecutive negative co-tests within the last 10 years
  • Most recent test occurred within the last 5 years
  • No history of high-grade precancerous lesions (CIN 2 or 3) or cervical cancer
  • Not otherwise at high risk for cervical cancer

Critical Exceptions Requiring Continued Screening Beyond Age 65

Women with a history of CIN 2, CIN 3, or adenocarcinoma in situ must continue routine screening for at least 20 years after treatment, even if this extends screening past age 65. 5, 4 This is non-negotiable due to persistent elevated cancer risk.

Women with lower-grade abnormalities (ASC-US, LSIL, or CIN 1) must demonstrate adequate negative screening AFTER resolution of the abnormality before standard cessation criteria apply. 5

High-risk women (HIV-positive, immunocompromised, history of cervical cancer) should continue annual screening and not follow standard cessation guidelines. 4

When NOT to Screen

Do not screen women who have had a total hysterectomy with removal of the cervix unless they have a history of high-grade precancerous lesions or cervical cancer. 1, 4, 3 Screening provides no benefit in this population.

HPV Testing Guidelines

Appropriate Uses

  • Triage of women aged ≥21 years with ASC-US cytology results 1
  • Routine co-testing with Pap test in women aged ≥30 years 1

Inappropriate Uses (Never Use HPV Testing For)

  • Women younger than 30 years for routine screening 1, 4
  • Deciding whether to vaccinate for HPV 1
  • STD screening 1
  • Stand-alone primary screening without Pap test 1

Common Pitfalls to Avoid

Over-screening remains a significant problem, with only 19-31% of physicians recommending guideline-concordant intervals. 4, 6 Most continue to screen annually, which increases costs and potential harms without improving cancer detection. 4

Many women equate having a pelvic examination with having a Pap test when no sample was actually taken. 1 Provide written documentation stating whether a Pap test was obtained during the visit, as self-reports are often inaccurate. 1, 4

Physicians are less likely to extend screening intervals when using co-testing compared to Pap alone, despite guidelines supporting 5-year intervals with co-testing. 6 Only 19% of physicians recommend the next Pap test in 3 years after a normal co-test result. 6

Special Populations

Women with immunosuppression, history of multiple sexual partners, smoking, pessary use, or high-risk ethnicity (Vietnamese or Hispanic) may require continued screening beyond age 65 even with adequate negative screening history. 5

Pregnant women should follow the same screening recommendations as non-pregnant women. 1

Women who have received HPV vaccination should be screened using the same recommendations as unvaccinated women. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cervical Cancer Screening Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Cervical Cancer Screening Guidelines for Asymptomatic Women

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Cervical Cancer Screening Guidelines for Women with Abnormal Pap History

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.